- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07306962
Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
Does Computer-assist Virtual Lesion Segmentation Ushers to a Change in the Literature Consensus Regarding Mandibular Ameloblastoma Radiographic Safety Margin?. A Clinical Case Series
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: yehia A El-Mahallawy., PhD
- Phone Number: 002 +201007217014.
- Email: yehia.el-mahallawy@alexu.edu.eg
Study Locations
-
-
Alexandria Governorate
-
Alexandria, Alexandria Governorate, Egypt, 21523
- Recruiting
- Faculty of Dentistry, Alexandria University
-
Contact:
- Yehia A El-Mahallawy, PhD
- Phone Number: +201007217014
- Email: yehia.el-mahallawy@alexu.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with histologically confirmed ameloblastoma using a preoperative biopsy.
- Patients with ameloblastoma that require segmental mandibular continuity defect, not involving the condyle.
Exclusion Criteria
- Patients with lateral segmental mandibular defect involving the condyle.
- Patients with an active infection at the site of resection.
- Patients with recurrent lesion after resection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Virtual lesion segmentation for mandibular ameloblastoma
Patient with mandibular ameloblastoma managed with virtual surgical planning & Virtual lesion segmentation for the determination of a radiographic 10-mm safety margin.
|
Patient with mandibular ameloblastoma managed with virtual surgical planning & Virtual lesion segmentation for the determination of a radiographic 10-mm safety margin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Histological analysis and degree of lesion invasion determination
Time Frame: 1 month
|
The specimen with the the mounted Safety Margin Calibration Guide will be sent for histological evaluation. For light microscopic examination, the specimens will be embedded in paraffin wax blocks after being fixed in 10% formalin, neutrally buffered, cleaned, and dehydrated using increasing ethanol concentrations. Tissue sections will be cut to a thickness of 4 μm, and stained with hematoxylin and eosin to be examined under a light microscope. The specimen will be cut, using the S35 (0.254-mm thickness) microtome blade, at the preoperatively determined margins according to the virtual lesion segmentation from the proximal and distal sides of the lesion. Since the study is limited to segmental mandibular resection, the full lower border of the mandible was resected and their will be no need for assessment of either coronal or apical margins |
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative resection margin accuracy analysis
Time Frame: 1 week
|
At the end of the surgical procedure, the Safety margin caliberation guide was mounted on the specimen and fixed using 2 2.0-mm miniscrews.
A radiographic MSCT scan for the resected mandible with the Safety margin caliberation guide will be obtained using same preoperative scanning parameters.
The DICOM data of the scanned Specimen will be segemented to create an Actual Resected Specimen Model (ARSM).
The RSM will be superimposed with the preoperative Virtual Resected Specimen Model (VRSM) using the miniscrews as radiographic markers for superimposition.
The postoperative accuracy of the virtually assisted surgery will be conducted using the 3D-analysis software (GOM-Inspect software*) For each of the selected 2D and 3D parameters, the Deviation will be calculated by subtracting the ARSM values from the VRSM.
The absolute mean (Δ) for all of the operated patients will be calculated
|
1 week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: yehia A El-Mahallawy, Phd, Faculty of Dentistry, Alexandria University, Alexandria, Alexandria
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-12-25/SM-Amelo
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ameloblastoma
-
Minia UniversityCompleted
-
Stanford UniversityNovartis PharmaceuticalsCompletedAmeloblastoma | BRAF Gene MutationUnited States
-
Shandong UniversityNot yet recruiting
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruiting
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingBRAF V600E Mutation Positive | AmeloblastomaChina
-
Shanghai Ninth People's Hospital Affiliated to...CompletedCystic Cavity Area Reduction Efficiency | the Recurrence of the Tumor